Communiqués PAVmed Inc.

Actions

PAVM

US70387R5028

Equipement et technologie médicale avancés

Temps Différé Nasdaq 16:56:33 23/09/2026			Varia. 5j.	Varia. 1 janv.
4,050 ^USD	-3,17%		+3,32%	-38,86%

14/08	Transcript : PAVmed Inc., Q2 2026 Earnings Call, Aug 14, 2026
13/08	PAVmed Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

27/08/25	Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025	PR
14/08/25	PAVmed : Q1 2025	PU
13/08/25	Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results	PR
05/08/25	Lucid Diagnostics to Participate in Upcoming Investor Conferences	PR
31/07/25	PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025	PR
30/07/25	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025	PR
30/07/25	PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule	PR
16/07/25	MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test	PR
24/06/25	PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing	PR
18/06/25	Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test	PR
03/06/25	PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	PR
27/05/25	Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes	PR
14/05/25	Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results	PR
30/04/25	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025	PR
11/04/25	Lucid Diagnostics Announces Closing of Public Offering of Common Stock	PR
10/04/25	Lucid Diagnostics Announces Pricing of Public Offering of Common Stock	PR
09/04/25	Lucid Diagnostics Announces Proposed Public Offering of Common Stock	PR
03/04/25	Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference	PR
27/03/25	Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology	PR
25/03/25	PAVmed : FY 2024	PU
13/03/25	Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test	PR
11/03/25	PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025	PR
10/03/25	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025	PR
05/03/25	Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering	PR
04/03/25	Lucid Diagnostics Announces $15.3 Million Registered Direct Offering	PR